Diagnostic Pathways


State of the Art Care in Alzheimer's Disease: Exploring the Role of Biomarkers

Michael Weiner, MD, Sharon Cohen, MD, FRCPC, Oskar Hansson, MD, PhD

Are you up to date on how the field of Alzheimer's disease diagnosis is changing? Learn from Michael Weiner, MD, Sharon Cohen, MD, FRCPC, and Oskar Hansson, MD, PhD about current and emerging biomarkers of Alzheimer's disease, and improve your ability to describe biomarkers measured in Alzheimer's disease (AD), the relationship between AD biomarkers and clinical disease expression, and how biomarkers are used in clinical practice in the care of patients with AD.


Biomarker innovation in Alzheimer’s disease Learning Zone

Charlotte Teunissen, Professor of Neurochemistry at the Vrije Universiteit Amsterdam, Netherlands

Professor Charlotte Teunissen describes the benefits and limitations of using diagnostic biomarkers in Alzheimer’s disease, and reviews the latest innovations concerning neuroimaging, CSF and blood-based biomarkers
- Focus on neuroimaging and CSF biomarkers to help confirm an Alzheimer’s diagnosis
- Learn validation evidence for new blood-based biomarkers that meets some unmet needs


Improving the Early Detection of Alzheimer’s Disease Pathology: Advances in Cerebrospinal Fluid-Derived Biomarkers

Douglas R. Galasko, MD; Leslie M. Shaw, PhD; Henrik Zetterberg, MD, PhD

During this panel discussion with Leslie M. Shaw, PhD and Henrik Zetterberg, MD, PhD, moderated by Douglas R. Galasko, MD, you will learn how to better identify clinically relevant biomarkers in AD, differences between available biomarkers, and how to interpret the results of biomarker testing. CMEs are available as part of this education.

Fluid biomarkers


Understanding the clinical value of fluid biomarkers in Alzheimer's disease

This set of five interactive learning modules will explore various concepts on the clinical application of CSF and blood-based biomarkers in the timely diagnosis of Alzheimer's disease. Such titles include:
- Understanding the clinical value of CSF biomarkers
- Using standardised CSF testing to support a timely diagnosis
- Optimising the diagnostic pathway with fluid biomarkers
- Examining the significance of robustness for the clinical use of blood-based biomarkers
- Recognising the clinical value of CSF biomarkers through real-world case studies

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.